- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
TPA for Retained Hemothorax: Safety Analysis by Injury Pattern and Mechanism (Location:Boston Convention and Exhibition Center, Room 258B) - May 30, 2022 - Abstract #SIR2022SIR_1518;
Intrapleural tPA administration could reduce the need for surgery in patients with retained hemothorax. More research is needed to understand the relationship between risk of tPA and mechanism and injury pattern.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Reduced Severity of Tissue Injury Within the Infarct May Partially Mediate the Benefit of Reperfusion in Ischemic Stroke. (Pubmed Central) - May 29, 2022
In patients with ischemic stroke, reduced severity of tissue injury within the infarct, as determined by assessing the integrity of the BBB, is independently associated with improved functional outcome. In addition to reducing diffusion-weighted imaging-defined infarct volume, reperfusion may also improve clinical outcome by reducing tissue injury severity within the infarct.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Clinical data, Retrospective data, Journal: Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial. (Pubmed Central) - May 29, 2022
P=N/A
For patients with large vessel occlusion directly presenting to an endovascular treatment-capable hospital, intravenous alteplase increases early reperfusion when endovascular treatment gets delayed more than approximately half an hour. Thus, intravenous alteplase should be considered if endovascular treatment delays are anticipated by the treating medical team.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Role of Intravenous Thrombolytics Prior to Endovascular Thrombectomy. (Pubmed Central) - May 29, 2022
We conclude that, pending individual-patient data meta-analyses, intravenous thrombolytics retain an important role alongside endovascular thrombectomy. Further efforts to accelerate and enhance reperfusion with thrombolytics and perform individual patient-level pooled subgroup analyses are warranted.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Effect of mechanical thrombectomy with vs. without intravenous thrombolysis in acute ischemic stroke. (Pubmed Central) - May 26, 2022
The incidence of symptomatic intracerebral hemorrhage was not significantly different between groups (6 [5.3%] vs. 1 [1.6%]; P = 0.42). Among patients with AIS due to LVO in our study, MT alone was noninferior in terms of functional outcomes compared with MT preceded by the administration of intravenous alteplase within 4.5 hours after symptom onset.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Retrospective data, Review, Journal: Mechanical Thrombectomy and Intravenous Thrombolysis in Patients with Acute Stroke: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - May 26, 2022
Among patients with AIS due to LVO in our study, MT alone was noninferior in terms of functional outcomes compared with MT preceded by the administration of intravenous alteplase within 4.5 hours after symptom onset. Direct E-MT alone led to acceptable outcomes even in comparison to E-MT with tPA, whereas additional tPA did not cause higher risk of symptomatic intracranial hemorrhage.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Cryoprecipitate for Alteplase-Related Hemorrhagic Conversion of Acute Ischemic Stroke. (Pubmed Central) - May 21, 2022
Cryoprecipitate was associated with a low rate of thrombosis and hemostasis for alteplase-associated hemorrhagic conversion of acute ischemic stroke. There was significant heterogeneity in treatment regimens, including the use of and dosing of adjunctive aminocaproic acid and monitoring of fibrinogen levels.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim
Review, Journal: Tenecteplase in Ischemic Stroke: Challenge and Opportunity. (Pubmed Central) - May 20, 2022
TNK has the potential to substitute alteplase for ischemic stroke therapy. Future TNK clinical trials that target functional outcomes are warranted.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Trial completion, Phase classification, Enrollment change: CHOICE: Intraarterial Alteplase Versus Placebo After Mechanical Thrombectomy (clinicaltrials.gov) - May 20, 2022
P2/3, N=121, Completed,
Alteplase thrombolysis showed benefits in mitigating the coagulation function and nerve function damage of patients with ischemic stroke, especially within 3 hours after the onset, with a high safety profile. Recruiting --> Completed | Phase classification: P2 --> P2/3 | N=200 --> 121
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Review, Journal: Thrombolytic Salvage of the Frostbitten Upper Extremity: A Systematic Review. (Pubmed Central) - May 19, 2022
Patient and nurse surveys indicated that peer nurse mentoring increased nurse and patient confidence and competence in making the practice transition. Thrombolytics, particularly when administered by the intra-arterial route, are emerging as a promising treatment of severe frostbite of the upper extremity, increasing digit salvage rates.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical, Pricing, Journal, HEOR: Is concurrent intravenous alteplase in patients undergoing endovascular treatment for large vessel occlusion stroke cost-effective even if the cost of alteplase is only US$1? (Pubmed Central) - May 19, 2022
P=N/A
Thrombolytics, particularly when administered by the intra-arterial route, are emerging as a promising treatment of severe frostbite of the upper extremity, increasing digit salvage rates. EVT without concurrent alteplase is the preferred strategy from a health economic standpoint.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: High-resolution CT with arch/neck/head CT angiography on a mobile stroke unit. (Pubmed Central) - May 19, 2022
EVT without concurrent alteplase is the preferred strategy from a health economic standpoint. MSU use of advanced imaging including multiphasic head/neck CTA is feasible, offers high LVO yield and enables full ED bypass.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
P3 data, Journal, Head-to-Head: Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial. (Pubmed Central) - May 18, 2022
P3
Our study consequently could not show that 0·4 mg/kg tenecteplase is non-inferior to alteplase in moderate and severe ischaemic stroke. Future stroke trials should assess a lower dose of tenecteplase versus alteplase in patients with moderate or severe stroke.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
P2 data, Journal: Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial. (Pubmed Central) - May 18, 2022
P2
Treatment with tenecteplase on the MSU in Melbourne resulted in a superior rate of early reperfusion compared with alteplase, and no safety concerns were noted. This trial provides evidence to support the use of tenecteplase and MSUs in an optimal model of stroke care.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ETHICS OUTCOMES OF THE ALTEPLASE COMPARED TO TENECTEPLASE (ACT) TRIAL () - May 18, 2022 - Abstract #ESOC2022ESOC_1861;
In this acute stroke study that enrolled all patients by deferral of consent, very few patients withdrew from the study or were unhappy about having been enrolled. This survey reports the attitudes of the largest sample to date of patients enrolled by deferral of consent into an acute stroke trial, supporting the use of both deferral and advance consent.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
EFFECT OF INTRA-ARTERIAL ALTEPLASE FOLLOWING SUCCESSFUL THROMBECTOMY ON BRAIN IMAGING: A NESTED STUDY OF THE CHOICE RANDOMIZED TRIAL () - May 18, 2022 - Abstract #ESOC2022ESOC_1811;
This survey reports the attitudes of the largest sample to date of patients enrolled by deferral of consent into an acute stroke trial, supporting the use of both deferral and advance consent. Among patients with acute ischemic stroke and successful reperfusion following thrombectomy, adjunct IA-rtPA compared with placebo resulted in a significant reduction of microvascular hypoperfusion and infarct expansion and improved markers of neuronal integrity.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Journal: Significant Vision Recovery from Filler-Induced Complete Blindness with Combined Intra-Arterial Injection of Hyaluronidase and Thrombolytic Agents. (Pubmed Central) - May 15, 2022
We immediately performed an injection of 1500 IU hyaluronidase combined with 8 mg alteplase for intra-arterial thrombolysis (IAT) into the right ophthalmic artery...This case demonstrates that reversal of complete blindness due to embolism of the ophthalmic and central retinal arteries could be accomplished through multidisciplinary therapies, especially IAT using fibrinolytic agents combined with hyaluronidase followed by an anticoagulant regimen.Level of evidence VThis journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine Ratings, please refer to Table of Contents or online Instructions to Authors www.springer.com/00266 .
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Observational data, Retrospective data, Journal: MRI-guided thrombolysis for lenticulostriate artery stroke within 12 h of symptom onset. (Pubmed Central) - May 15, 2022
Thrombolysis was administered via tissue plasminogen activator, alteplase (TPA)...However, in all groups, the onset-to-treatment time did not significantly influence the outcomes. We conclude that in our cohort higher admission systolic blood pressure and higher baseline NIHSS and not time were associated with poor outcome in patients with magnetic resonance-guided thrombolysis within 12 h of isolated lenticulostriate artery stroke, therefore loosening the traditionally perceived dependency of outcome on time.
- |||||||||| Entresto (sacubitril/valsartan) / Novartis, ROVI Pharmaceuticals Laboratories, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
PK/PD data, Journal: An Overview of Clinically Imperative and Pharmacodynamically Significant Drug Interactions of Renin-Angiotensin-Aldosterone System (RAAS) Blockers. (Pubmed Central) - May 14, 2022
Clinicians, pharmacists, and other health-care practitioners should be accountable for medication safety. To avoid adverse implications, prescribers and pharmacists must be aware of the drugs that interact with RAAS blockers.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
ENDOVASCULAR TREATMENT FOR UPPER AND LOWER EXTREMITYDEEP VEIN THROMBOSIS, CASE REPORTS () - May 13, 2022 - Abstract #EHA2022EHA_2548;
After the first procedure, complete venous patency was achieved in 3 patients (15%), 11 patients (55%) almost complete, partial recanalization in 4 patients (20%) and failure in recanalization in 2 patients(10%).After 24 hours of thrombolytic infusion with alteplase or urokinase: 11patients required additional angioplasty and 6 patients needed stent placement...Endovascular therapy should be performed in selected patients who present a low risk of bleeding. It is important to implement a close monitoring of laboratory parameters.
- |||||||||| Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Thrombolytic therapy in pulmonary embolism patients with thrombocytopenia: a systematic review (Exhibition) - May 13, 2022 - Abstract #ISTH2022ISTH_1618;
The average age of cases presenting with PE and thrombocytopenia who received thrombolysis was 50.5 years, with 54.5% females. Dyspnea (58.3%), Orthopnea (50%), and lower limb pain (25%) were the most commonly reported clinical findings.
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Enrollment open, Trial completion date, Trial primary completion date: NOR-TEST 2: The Norwegian Tenecteplase Stroke Trial 2 (clinicaltrials.gov) - May 10, 2022
P3, N=201, Recruiting,
Baseline infarct size may not modify the effect of alteplase prior to endovascular thrombectomy with regard to favorable functional outcomes and adverse events. Active, not recruiting --> Recruiting | Trial completion date: Jan 2022 --> Sep 2023 | Trial primary completion date: Sep 2021 --> Sep 2023
- |||||||||| TNKASE (tenecteplase) / Roche, Boehringer Ingelheim, Activase (alteplase) / Roche, Boehringer Ingelheim, Kyowa Kirin, Mitsubishi Tanabe
Clinical protocol, P2 data, Journal, Head-to-Head: Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit. (Pubmed Central) - May 7, 2022
P2
The findings will be published in peer-reviewed journals, presented at academic conferences and disseminated among consumer and healthcare professional audiences. NCT04071613.
|
